Nedosiran population pharmacokinetic and pharmacodynamic modelling and simulation to guide clinical development and dose selection in patients with primary hyperoxaluria type 1
British Journal of Clinical Pharmacology · 2024
DOI: 10.1111/bcp.16194 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Steven Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Dicerna Pharmaceuticals, Inc. a Novo Nordisk company, Lexington, Massachusetts, USA. Hauptthemen laut MEDLINE: Hyperoxaluria, Primary, Models, Biological, Computer Simulation, Glomerular Filtration Rate. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk.
Abstract (Originalsprache)
Aim
To characterize pharmacokinetic and pharmacodynamic profiles of nedosiran in patients with primary hyperoxaluria type 1 (PH1), identify influential covariates and confirm therapeutic doses.
Methods
A population pharmacokinetic (PK)/pharmacodynamic (PD) (POP‐PKPD) model was developed to characterize the concentration‐time course of nedosiran and the corresponding effect on 24‐h urinary oxalate ( U ox ) . Simulations of dosing to achieve clinically meaningful reduction in U ox in children, adolescents and adults with PH1 were performed.
Results
Analyses included PK data from 143 healthy participants and PH1/PH2 patients, and PD data from 46 PH1 patients. Nedosiran PK was described by a two‐compartment model with dual n‐transit absorption and parallel linear and nonlinear elimination. The relationship between nedosiran exposure and U ox was described by an indirect response model. Body weight, estimated glomerular filtration rate (eGFR) and disease status were identified as influential covariates for the POP‐PK model. The simulation results supported a weight‐banded dosing regimen of nedosiran sodium in adolescents and adults (≥12 years) with PH1 of 170 mg (weight ≥50 kg) and 136 mg (weight
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dicerna Pharmaceuticals, Inc. a Novo Nordisk company, Lexington, Massachusetts, USA.
- Pyxis Oncology, Boston, Massachusetts, USA.
- BioNTech US Inc., Cambridge, Massachusetts, USA.
- Parexel International, Brisbane, Queensland, USA.
- Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA.
Förderung
- Novo Nordisk
Zitieren
APA
Zhang, S., Amrite, A., Tan, B., Jamsen, K., Pradhan, S., Choy, S., & Plotkin, H. (2024). Nedosiran population pharmacokinetic and pharmacodynamic modelling and simulation to guide clinical development and dose selection in patients with primary hyperoxaluria type 1. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16194
Vancouver
Zhang S, Amrite A, Tan B, Jamsen K, Pradhan S, Choy S, et al. Nedosiran population pharmacokinetic and pharmacodynamic modelling and simulation to guide clinical development and dose selection in patients with primary hyperoxaluria type 1. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16194
BibTeX
@article{Zhang2024,
author = {Zhang, Steven and Amrite, Aniruddha and Tan, Beesan and Jamsen, Kris and Pradhan, Sudeep and Choy, Steve and Plotkin, Horacio},
title = {Nedosiran population pharmacokinetic and pharmacodynamic modelling and simulation to guide clinical development and dose selection in patients with primary hyperoxaluria type 1},
journal = {British Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1111/bcp.16194}
}
EUVIMED